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The role of dengue virus-specific serotype-cross-reactive T lymphocytes in recovery from and pathogenesis of dengue
virus infections is not known. In the present paper, we have defined a dengue serotype-cross-reactive epitope recognized by
two CD41 CD82 cytotoxic T lymphocyte (CTL) clones, JK36 and JK46. These T cell clones were established from the
peripheral blood T lymphocytes of a dengue-3-immune donor, using a limiting dilution method. JK36 and JK46 were
cross-reactive for dengue virus types 2, 3, and 4, but not for type 1, and recognized the NS3 protein. The smallest synthetic
peptide recognized by JK36 was an 8-amino acid peptide that contains amino acids (aa) 226 to 233 (VVAAEMEE) of NS3. The
smallest peptide recognized by JK46 was an 11-amino acid peptide that contains aa 224 to 234 (TRVVAAEMEEA). HLA-DR15
was the restriction allele for recognition of these peptides by both JK36 and JK46. This is the first epitope to be defined that
is recognized by human CD41 CTL cross-reactive for dengue virus types 2, 3, and 4. © 1998 Academic Press
INTRODUCTION
Dengue viruses are members of the family Flaviviridae
and are transmitted to humans mainly by Aedes aegypti
mosquitoes (Monath, 1994) Four serotypes of dengue
virus, types 1, 2, 3, and 4, exist. Infection with any of the
four serotypes of dengue viruses can result in an asymp-
tomatic infection, a self-limited febrile disease (dengue
fever, DF), or a severe, life-threatening illness (dengue
hemorrhagic fever, DHF) (Halstead, 1988). The pathogen-
esis of DHF is not understood. It, however, has been
hypothesized that DHF is caused by immunopathology,
based on the observation that DHF is more commonly
observed after a secondary infection with a serotype of
dengue virus different from that which caused primary
infection (Halstead, 1980).
Primary infection with one serotype of dengue virus
induces virus-specific CD41 and CD81 memory T lym-
phocytes (Kurane and Ennis, 1994). These include (i)
serotype-specific, (ii) dengue serotype-cross-reactive,
and (iii) flavivirus-cross-reactive T lymphocytes. The pat-
terns of serotype-cross-reactivities are heterogeneous.
We have previously reported CD41 T lymphocytes which
are cross-reactive for all the four serotypes (Kurane et al.,
1991), cross-reactive for dengue 1, dengue 2, and dengue
3 (Kurane et al., 1991; Zeng et al., 1996), cross-reactive for
dengue 2, dengue 3, and dengue 4 (Kurane et al., 1991),
cross-reactive for dengue 1, dengue 3, and dengue 4
(Kurane et al., 1991), cross-reactive for dengue 2 and
dengue 4 (Livingston et al., 1995), and cross-reactive for
dengue 1 and dengue 3 (Green et al., 1993). We have
also reported CD81 cytotoxic T cell clones cross-reac-
tive for dengue 2 and dengue 4 (Livingston et al., 1995).
It is likely that these serotype-cross-reactive T lympho-
cytes are activated by a secondary infection with a se-
rotype different from that which caused the primary in-
fection. These cross-reactive T lymphocytes probably
play an important role in immune responses by providing
help for antibody production and by lysing virus-infected
cells. On the other hand, these cross-reactive CD41 T
cells may contribute to immunopathology in DHF (Kurane
and Ennis, 1992). Definition of the epitopes recognized
by dengue virus-specific T cells is critical for subunit
vaccine development. Cross-reactive CD41 T cell
epitopes should not be included in the subunit vaccines
if serotype-cross-reactive CD41 T cells are shown to
contribute to immunopathology. The present study de-
fines the first epitope recognized by human CD41 CTL
that are cross-reactive for dengue 2, dengue 3, and
dengue 4.
RESULTS
Determining the localization of the epitope recognized
by JK36 and JK46, using dengue–vaccinia
recombinant viruses
We previously reported that JK36 and JK46 were cross-
reactive for dengue-2, dengue-3, and dengue-4 viruses,
but did not recognize dengue 1 virus, yellow fever virus,
or West Nile virus (Kurane et al., 1991). The protein
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recognized by JK36 and JK46 was determined to be NS3
protein (Kurane et al., 1991).
We first examined the localization of the epitopes rec-
ognized by JK36 and JK46 using recombinant vaccinia
viruses which expressed truncations of dengue-3 NS3
(Table 1). JK36 lysed the target cells infected with recom-
binant vaccinia viruses expressing aa 1–548, aa 1–285,
and aa 1–248, but did not lyse those infected with re-
combinant vaccinia viruses expressing aa 1–214 or aa
1–83. JK46 lysed target cells infected with recombinant
vaccinia viruses expressing aa 1–548 and aa 1–374.
These results indicate that the epitopes recognized by
JK36 and JK46 are located between aa 214 and aa 247,
and between aa 1 and aa 374, respectively. Clones JK36
and JK46 had the same serotype specificities, and we
suspected that these CTL clones might recognize the
same epitope.
Mapping of the epitope on NS3 using synthetic
peptides
We next examined six 15-aa peptides which covered
the region from aa 221 to aa 250 of dengue-3 and den-
gue-4 NS3 for recognition by the CTL clones (Table 2).
The peptides D3.NS3.221 and D4.NS3.221, which con-
tained aa 221–235 of NS3 of dengue 3 or dengue 4, were
recognized by both T cell clones. JK36 also recognized
the peptides D3-89-5 and D4-89-5 to some degree at 25
mg/ml, but did not recognize D3.NS3.236 or D4.NS3.236.
JK46 did not recognize any of the other four peptides.
To delineate the smallest peptide recognized by these
clones, we synthesized N and C terminus truncations of
the peptide D4.NS3.221 and examined the recognition of
these peptides by JK36 and JK46 (Table 3). Peptides
D4.NS3.221 a, b, c, e, f, h, i, j, and k were recognized by
JK36, while peptides D4.NS3.221a, e, and h were recog-
nized by JK46. These results indicate that the 8-aa pep-
tide D4.NS3.221k, representing aa 226–233, and the
11-aa peptide D4.NS3.221h, representing aa 224–234,
were the smallest unit recognized by JK36 and JK46,
respectively. It should, however, be noted that 9-aa pep-
tide D4.NS3.221j was recognized at 2.5 mg/ml to some
extent by JK36, while D4.NS3.221k was not recognized at
2.5 mg/ml.
HLA DR15-restricted recognition of the epitope
HLA restriction of the JK36 and JK46 clones were
analyzed using HLA-defined allogeneic target cells in
TABLE 1
Recognition of Recombinant Vaccinia Viruses Expressing
Truncations of NS3 by JK36 and JK46a
Target cells
infected or
pulsed with
Amino
acids
on NS3
% Specific 51Cr release
JK36
Exp. 1 Exp. 2 JK46, Exp. 1
VV-D3NS3 1–618 25 ND 19
VV-D3-5 1–548 NDb 43 25
VV-D3-10 1–374 ND ND 35
VV-D3-6 1–285 20 40 ND
VV-D3-8 1–247 ND 26 ND
VV-D3-3 1–214 4 ND ND
VV-D3-7 1–83 0 ND ND
VV-control None 0 2 0
Dengue 3 Ag 19 20 44
Control Ag 0 7 ND
a Effector:target ratios were 17:1 (Exp. 1) and 20:1 (Exp. 2) for JK36
and 20:1 for JK46; 5-h assay.
b ND, not done.
TABLE 2
Recognition of the Peptides D3.NS3.221 and D4.NS3.221a
Peptides Amino acids on NS3
% Specific 51Cr releaseb
JK36 JK46
25 mg/ml 2.5 mg/ml 25 mg/ml 2.5 mg/ml
Exp. 1 D3.NS3.221c 221–235 61 20 44 29
D3-89-5 227–241 16 3 7 5
D4-89-5 227–241 18 0 4 0
D3.NS3.236 236–250 8 0 8 3
Exp. 2 D4.NS3.221c 221–235 53 36 59 49
D3-89-5 227–241 6 0 8 3
D4-89-5 227–241 23 1 13 4
D4.NS3.236 236–250 0 0 NDd ND
a Effector:target ratios were 20:1 for JK36 and 8:1 for JK46 in experiment 1, 5:1 for JK36, and 7:1 for JK46 in experiment 2, 5-h assay.
b % Specific 51Cr release without peptide was 0% with JK36 and 5% with JK46.
c Amino acid sequences of the peptides D3.NS3.221 and D4.NS3.221 were LAPTRVVAAEMEEAM and LAPTRVVAAEMEEAL, respectively. Amino
acid residues were different only at the aa position 235 between dengue 3 and dengue 4 viruses.
d ND, not done.
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cytotoxic assays (Table 4). The allogeneic target cells
which shared the HLA-DR15 (5DR2) allele were recog-
nized in the presence of the D4.NS3.221 or D3.NS3.221
peptides, but other target cells which did not share
HLA-DR15 (or DR2) were not recognized. These results
suggest that the recognition of the epitope by JK36 and
JK46 is HLA-DR15-restricted.
DISCUSSION
The epitope on NS3 recognized by two dengue virus
serotype-cross-reactive CD41 CD82 T cell clones, JK36
and JK46, was mapped. These two CD41 CTL clones
recognized dengue-2, dengue-3, and dengue-4 viruses,
but did not recognize dengue-1. The minimum recogni-
TABLE 3
Definition of the Minimum Unit of the Epitope Recognized by JK36 and JK46a
Peptides Amino acids on NS3 Amino acid sequences
% Specific 51Cr releaseb
JK36 JK46
25 mg/ml 2.5 mg/ml 0.25 mg/ml 25 mg/ml 2.5 mg/ml 0.25 mg/ml
Exp. 1 D4.NS3.221 221–235 LAPTRVVAAEMEEAL 68 45 9 46 29 5
D4.NS3.221a 224–235 TRVVAAEMEEAL 68 60 12 33 7 4
D4.NS3.221b 225–235 RVVAAEMEEAL 72 57 5 6 5 3
D4.NS3.221c 226–235 VVAAEMEEAL 73 17 3 5 2 4
D4.NS3.221d 227–235 VAAEMEEAL 5 1 0 8 NDc ND
D4.NS3.221e 221–234 LAPTRVVAAEMEEA 71 22 0 40 11 4
D4.NS3.221f 221–233 LAPTRVVAAEMEE 49 4 2 11 4 3
Exp. 2 D4.NS3.221 221–235 LAPTRVVAAEMEEAL 71 52 12 36 14 3
D4.NS3.221e 221–234 LAPTRVVAAEMEEA 74 34 6 17 3 2
D4.NS3.221h 224–234 TRVVAAEMEEA 82 60 15 15 3 1
D4.NS3.221i 225–234 RVVAAEMEEA 73 31 4 2 1 2
D4.NS3.221j 226–234 VVAAEMEEA 72 17 2 2 2 2
D4.NS3.221k 226–233 VVAAEMEE 41 1 1 1 0 0
a Effector:Target ratios were 5:1 for JK36 and 3:1 for JK46 in Exp. 1 and 9:1 for JK36 and 5:1 for JK46 in Exp. 2, 5-h assay.
b % Specific lysis without peptide was 0% with JK36, 1% with JK46 in Exp. 1, and 2% with JK36 and 0% with JK46 in Exp. 2.
c ND, not done.
TABLE 4
HLA-DR15-Restricted Recognition of the Peptide by JK36 and JK46a
Target cells
HLA Class IIb
% Specific 51Cr release
JK36 JK46
DR DP DQ Peptidec None Peptidec None
Exp. 1
Autologus 15(52),103 W2 5(51),6(51) 87 1 34 NDd
9011 15 W2,W4 6 5 4 0 ND
VA-9 15, 17 ND 2, 6 81 0 25
VA-16 15, 13 ND 6, 7 36 0 8 ND
3107 2 W4 2 72 2 47 ND
9038 12 W2 7 0 1 0 ND
MS 1, 4 W4 1, 3 4 3 1 ND
9087 3 W3,W4 2 0 0 0 ND
Exp. 2
Autologous 15(52),103 W2 5(51),6(51) 76 2 24 0
63390 2, 5 ND 1, 3 65 0 19 1
JC 2, 4 ND 1, 3 0 0 0 0
3161 2 ND 2 44 4 12 0
9004 1 ND 5 2 0 0 3
a Effector:target ratio was 10:1, 5-h assay.
b Underlines indicate HLA alleles shared with autologous target cells.
c D4.NS3.221 was used at 10 mg/ml in Exp. 1, and D3.NS3.221 was used at 10 mg/ml in Exp. 2.
d ND, not done.
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tion unit of the epitope (VVAAEMEE) recognized by JK36
is 8 amino acids in length and is located between aa 226
and aa 233 of dengue-2, dengue-3, and dengue-4 vi-
ruses. The epitope (TRVVAAEMEEA) recognized by JK46
consists of 11 amino acids located between aa 224 and
aa 234. The amino acid sequences in this region of NS3
for other flaviviruses are shown in Table 5. Dengue-2,
dengue-3, and dengue-4 have the same amino acid se-
quence as dengue-4 in this region (Irie et al., 1989;
Osatomi and Sumiyoshi, 1990), and this is consistent
with the serotype-cross-reactive recognition of den-
gue-2, dengue-3, and dengue-4 by JK36 and JK46. Den-
gue-1 has two amino acid substitutions; S for A at aa 229
and A for E at aa 232 (Fu et al., 1992). Yellow fever virus
has three amino acid substitutions; L for A at aa 228, S
for A at aa 229, and K for E at aa 232 (Mackow et al.,
1987). West Nile virus has one amino acid substitution; S
for E at aa 232 (Mackow et al., 1987). Comparison of
these amino acid sequences suggests that the amino
acid at position 232 of NS3 may be critical for the rec-
ognition by JK36 and JK46.
The experiments performed to determine HLA-restric-
tion in the recognition of the epitope provided somewhat
inconsistent but interesting results. In the antibody
blocking experiments, the lysis of the peptide-pulsed
target cells and of dengue Ag-pulsed target cells (Kurane
et al., 1991) were completely inhibited by the monoclonal
Ab S3/4 specific for HLA-DQ. On the other hand, alloge-
neic target cells which expressed HLA-DR15 (DR-2) were
lysed after being pulsed with the peptide. Monoclonal
antibody to HLA-DR, however, inhibited the lysis of pep-
tide-pulsed target cells by 40–60% (data not shown).
These results suggest that JK36 and JK46 are HLA-DR15-
restricted and that mAb to HLA-DQ could also inhibit
lysis, perhaps by blocking interaction between effector
and target cells. Two allogeneic cell lines which shared
HLA-DR15 or HLA-DR2 were not recognized by JK36 and
JK46 after they were pulsed with the epitope peptides
(Table 4). It is possible that these allogeneic cell lines
have different HLA alleles from the CTL donor, but were
serologically defined as HLA-DR15 or HLA-DR2.
A motif for the HLA-DR2 (5DR15)-binding peptide has
been reported based on the endogenous peptides iso-
lated from Epstein–Barr virus-transformed LCL which
have HLA-DR genotype of DRB1*1501, DRB5*0101 (Chicz
et al., 1992). This HLA-DR genotype is the same as the
genotype of our donor. The motif is axxxxxxxxxb, where
‘‘a’’ is I, L, or V and ‘‘b’’ is H, K, or R. The smallest peptide
recognized by JK36 has V at the 1st and 2nd position, but
does not have H, K, or R at the 11th position because it
is only eight amino acids in length. Interestingly, the
amino acid at the position 237, which is the 10th amino
acid from V at aa 226 on the amino acid sequence is R
on dengue-4 and dengue-2 NS3, and K on dengue-3 NS3
(Irie et al., 1989; Mackow et al., 1987; Osatomi and Su-
miyoshi, 1990). Thus, if we extend the epitope to the C
terminus by three amino acids, this potential extended
epitope has the reported motif for HLA-DR15-binding
peptides. It is possible that the peptides recognized by
JK36 and JK46 in vivo are longer than the minimum
recognition unit and include R or K at aa 236.
In this report, we have defined the first epitope recog-
nized by human T cells that cross-react for dengue-2,
dengue-3, and dengue-4. The role of serotype-cross-
reactive CD41 CTL in dengue virus infection is an im-
portant subject to be further elucidated. We hypothesize
that serotype-cross-reactive CD41 T cells contribute to
the pathogenesis of DHF via cytokine production as well
as via cytolytic activity (Kurane and Ennis, 1992). On the
other hand, cross-reactive T cells may also play an im-
portant role in recovery from secondary dengue virus
infection. The definition of additional epitopes recog-
nized by dengue virus-specific human CD41 and CD81 T
cells, and the role of cross-reactive T cells in vivo, will
provide important information for the development of
vaccines which can induce strong protective immunity,
but do not induce immune responses that may lead to
immunopathology of DHF.
MATERIALS AND METHODS
Preparation of dengue virus antigens
Dengue virus type 1, Hawaii strain; type 2, New Guinea
C strain; type 3, CH53489 strain; and type 4, 814669
strain; yellow fever virus (YFV) 17D strain; and West Nile
virus (WNV), E101 strain were used. Dengue virus, YFV,
TABLE 5
Amino Acid Sequences of Flaviviruses at the Region Which Corresponds to aa 224–234 of Dengue-3 NS3a
224 234
Dengue-3 virus T R V V A A E M E E A
Dengue-1 virus —b — — — — S — — A — —
Dengue-2 virus — — — — — — — — — — —
Dengue-4 virus — — — — — — — — — — —
Yellow Fever virus — — — — L S — — K — —
West Nile virus — — — — — — — — S — —
a The references that contain these sequences are listed under Discussion.
b —, Conserved amino acids compared to dengue-4 virus.
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and WNV antigens were prepared from dengue virus-
infected Vero cells as previously reported (Kurane et al.,
1989). Vero cells were infected with viruses at an approx-
imate multiplicity of infection of 1 plaque forming unit
(PFU) per cell and cultured in minimal essential medium
containing 2% fetal calf serum (FCS). When 50% of the
monolayer had developed visible cytopathic effects, cells
were removed with cell scrapers (Costar, Cambridge,
MA), washed three times with phosphate-buffered saline
(PBS) at 4°C, treated with 0.025% glutaraldehyde (Sigma
Chemical Co., St. Louis, MO) in PBS for 15 min at 4°C,
washed again three times with PBS, and resuspended in
RPMI. The cells were then sonicated with a sonic dis-
membrater (Fisher Chemical Co.) and centrifuged at 1500
g for 10 min. The supernatant fluid was collected and
used as the virus antigen. Control antigen was prepared
in a similar manner by using uninfected Vero cells. An-
tigen (3 ml) was obtained from 15 75-cm2 flasks (Costar)
of confluent Vero cells.
Establishment and characterization of dengue virus-
specific T cell clones, JK36 and JK46, using a limiting
dilution method
Peripheral blood specimens were obtained from a
donor 12 months after immunization with a live attenu-
ated experimental dengue-3 (CH53489) candidate vac-
cine (Innis et al., 1988). This donor had been immunized
with yellow fever vaccine 1 year before immunization
with the dengue-3 candidate vaccine. The HLA alleles of
this donor are DRB1*0103, DRB1*1501, DRB5*0101,
DQB1*0501, DQB1*0602, DPA1*01, and DPB1*0201,
which are serologically defined as HLA-DR103, DR15,
DR51, DQ5, DQ6, and DPw2 (Bodmer et al., 1994).
HLA-DR and HLA-DQ typing was performed by the Amer-
ican Red Cross. HLA-DP typing was performed by Dr.
Elaine Reed at College of Physicians and Surgeons of
Columbia University.
Dengue virus-specific T-cell clones were established
and maintained as previously reported (Kurane et al.,
1991). JK36 was established using dengue 3 Ag by clon-
ing 1 cell per well, and JK46 was established using
dengue 4 Ag by cloning 10 cells per well. JK36 and JK46
both have a CD31 and CD41 CD82 phenotype. These
clones were maintained in RPMI containing 10% human
AB serum and 10% T-cell growth factor (Cellular Prod-
ucts, Inc., Buffalo, NY) and were stimulated by dengue 3
Ag once every 2 weeks.
Recombinant vaccinia viruses
The NS3 genes of dengue 2 (New Guinea C strain) and
dengue 3 (H-87 strain) were amplified from genomic
RNAs using the RT-PCR method with primers which con-
tained unique BamHI and HindIII restriction sites (Zeng
et al., 1996). The resulting PCR product was ligated into
the vaccinia transfer plasmid, pGK19, which contains
both BamHI and HindIII restriction sites in its cloning
cassette. Transfection of pGK19-NS3 plasmids into vac-
cinia virus (VV), strain WY-infected CV-1 cells resulted in
recombination at the viral thymidine kinase gene locus.
VV recombinants which contained the dengue NS3 gene
were selected after growth in BudR (20 mg/ml), plaque
purified three times, and grown to titers of 0.5–5 3 108
PFU/ml on CV-1 cells. The presence of the NS3 gene in
recombinant VV-infected CV-1 cells was demonstrated
by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis and PCR (Zeng et al., 1996).
Peptide synthesis
Peptides were synthesized according to the published
amino acid (aa) sequences of the dengue-3 NS3 gene
(Osatomi et al., 1990) and the dengue-4 NS3 gene
(Mackow et al., 1987), using the Symphony peptide syn-
thesizer (Rainin Instruments, Woburn, MA) at the Univer-
sity of Massachusetts Peptide Core Facility. Amino acid
analyses to verify the amino acid composition of some of
the peptides were performed by Dr. Robert Carraway at
the University of Massachusetts Medical Center Peptide
Core Facility.
Preparation of lymphoblastoid cell lines
A lymphoblastoid cell line (LCL) was established by
infecting PBMC from the donor with Epstein–Barr virus
obtained from an infected marmoset cell line (B95-8) that
was purchased from the American Tissue Culture Col-
lection (ATCC) as previously reported (Kurane et al.,
1989a). The 10th International Histocompatibility Work-
shop lymphoblastoid cell lines (10w 9011, 9087, and 9038)
were purchased from the American Society for Histo-
compatibility and Immunogenetics (Lenexa, KS). The LCL
lines 3107 and 3161 were purchased from the NICMS
Human Genetic Mutant Cell Repository (Camden, NJ).
Preparation of target cells
Antigen-treated LCL target cells were prepared by
seeding 4 3 105 cells/well in 24-well cluster plates in a
final volume of 0.5 ml of RPMI containing 10% fetal calf
serum (FCS) and dengue antigen diluted 1:50 to 1:75.
Cells were incubated for 16 h with antigen at 37°C.
Dengue–vaccinia recombinant virus (VV-DEN)-infected
target cells were prepared by infecting 1 3 106 LCL with
VV-DEN at an m.o.i. of approximately 20 PFU/cell for 2 h.
After being washed twice, infected LCL were incubated
in RPMI containing 10% FCS at 37°C for 16–20 h and then
used as target cells. Target cells were labeled by incu-
bation with 0.25 mCi Na2
51CrO4 (New England Nuclear
Research Products, Boston, MA) for 45–60 min in 0.1 ml
of RPMI at 37°C. Following four washes to remove ex-
cess 51Cr, the target cells were counted and diluted to
1 3 104 cells/ml for use in the cytotoxicity assay.
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Cytotoxic assays
51Cr-labeled target cells (1 3 103) in 0.1 ml of RPMI
containing 10% FCS were added to each well in V-bottom
microtiter plates (Linbro Chemical Co., Hamden, CT).
Various concentrations of effector cells in 0.1 ml of RPMI
containing 10% FCS were added to each well to give the
described effector/target ratios. In cytotoxic assays us-
ing synthetic peptides, 1 3 103 target cells in 0.1 ml of
RPMI were incubated with the indicated concentration of
peptide in 0.05 ml for 30 min, and effector cells in 0.05 ml
were then added to each well. After incubation at 37°C
for 4 h, the supernatant fluid was collected from each
well and counted in an automatic gamma counter (Ska-
tron Instruments, Lier, Norway). The percentage specific
51Cr release was calculated by the following formula:
100 3 (cpm experimental release 2 cpm spontaneous
release)/(cpm maximal release 2 cpm spontaneous re-
lease).
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